Ticker

Analyst Price Targets — WEAV

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
August 19, 2026 12:59 amMark SchappelLoop Capital Markets$7.40$7.28TheFly Weave downgraded to Hold from Buy at Loop Capital
August 18, 2026 2:59 pmHannah RudoffPiper Sandler$7.40$7.29TheFly Weave downgraded to Neutral from Overweight at Piper Sandler
August 18, 2026 2:54 pmStifel Nicolaus$7.40$7.29TheFly Weave downgraded to Hold from Buy at Stifel
August 7, 2026 1:12 pmParker LaneStifel Nicolaus$8.00$5.31TheFly Weave price target lowered to $8 from $9 at Stifel
February 20, 2026 12:11 pmParker LaneStifel Nicolaus$9.00$5.70TheFly Weave price target lowered to $9 from $11 at Stifel
February 20, 2026 11:34 amPiper Sandler$8.00$5.70TheFly Weave price target lowered to $8 from $12 at Piper Sandler
January 6, 2026 12:50 pmRaymond James$10.00$7.18TheFly Weave downgraded to Outperform from Strong Buy at Raymond James
April 24, 2025 12:08 pmParker LaneStifel Nicolaus$16.00$9.67TheFly Weave price target lowered to $16 from $20 at Stifel
October 31, 2024 9:31 amMark SchappelLoop Capital Markets$18.00$13.56TheFly Weave price target raised to $18 from $15 at Loop Capital
October 31, 2024 7:29 amBrent BracelinPiper Sandler$17.00$13.79StreetInsider Weave Communications Inc (WEAV) PT Raised to $17 at Piper Sandler

Latest News for WEAV

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows. “Regulatory communications are the…

Business Wire • Sep 1, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)

BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire • Aug 24, 2026
Weave Communications Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Weave Communications, Inc. - WEAV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Weave Communications, Inc. (NYSE: WEAV) to Francisco Partners. Under the terms of the proposed transaction, shareholders of Weave will receive $7.40 in cash for each share of Weave that they own. KSF is seeking to…

Business Wire • Aug 21, 2026
Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy

LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today released its 2026 State of Healthcare Pulse Survey, a survey of 285 owners, office managers, and front desk staff across dental, specialty medical, optometry, and veterinary practices. The findings point to a clear consensus: manual administrative…

Business Wire • Aug 20, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for WEAV.

No House trades found for WEAV.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top